产品分类导航
Ginkgolide dripping pill
放大查看
Ginkgolide dripping pill

Ginkgolide dripping pill

更新时间:2026-02-27

价格:
地区: 成都市
是否提供样品:
立即询盘
收藏

产品详情

产品名称: Ginkgolide dripping pill
产品分类: 心脑血管及循环系统类制剂
产品关键词: Ginkgolide dripping pill
是否为生产商:
主要销售市场: 北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲
是否提供样品:

产品描述:

Active ingredients: bilobalide, ginkgolide A, ginkgolide B and ginkgolide C, etc.

Description: yellowish dripping pill, bitter.

Dosage Form: oral solid preparation.
Indications: For the prevention/treatment of ischemic cerebral disease.

Strength: 10mg/pill.
Storage: Keep airtight in a dry and cool place at normal temperature.

Packaging: Pottery bottle for medical use, 150 pills/bottle. (Can be customized based on customer's order.)

Shelf Life: 18 months
Usage and Administration: Ginkgolide dripping pill is given 30~50mg as single oral dose, 3 times a day.
Contradictions:
1. Patients with a history of hypersensitivity or adverse reaction to the product or any other finished Ginkgo products.
2. Patients with a history of severe hypersensitivity.
3. Contradicted in pregnant and lactating women.

 

Baiyu provide CDMO service for:

FDFs & APIs
Primary & secondary packaging
Warehousing
Commercial scale, pilot scale, laboratory scale

You are warmly welcomed to contact us for business cooperation.

剂型
Dosage Form

生产线(条)
Poduction Lines

年产能
Annual Capacity 

注射剂
Injection

8

650,000,000

口服固体制剂
Oral Solid

3

700,000,000

原料药和中间体
API & Intermediates

3

8,000 Kg

中药前处理和提取
TCM Extraction

2

5,000,000 Kg 

sales@baiyu.cn

www.baiyujituan.com

公司简介

四川宏明博思药业有限公司成立于2013年,专注于原料药和制剂的生产。现有员工400余人,主要生产高端剂型如注射剂、冻干粉针剂、片剂和胶囊剂。宏明博思的冻干粉针制剂生产线已获得EU GMP,并通过巴西ANVISA现场检查。目前四川宏明博思冻干粉针制剂的多个产品在巴西、智利、秘鲁、危地马拉、泰国、菲律宾、马来西亚、南非、澳大利亚等开展注册中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
注册资本:
企业规模(人):
业务类型:
成立日期:
年销售额:
主营产品类别:

该公司其他产品

Clindamycin Phosphate for Injection
Clindamycin Phosphate for Injection
Active ingredients: clindamycin phosphate. Description: white or off-white cake or powder. Dosage Form: lyophilized powder for injection. Strength: (1) o.3g; (2) 0.6g (Calculated by C18H33ClN2O5S). Indications: 1. For the treatment of a variety of infectious diseases caused by gram-positive bacteria. 2. For the treatment of a variety of infectious diseases caused by anaerobic bacteria. Storage: Keep airtight in a cool place at a temperature not above 20 ℃, protect from light. Packaging: tubular vial for antibiotic use, 10 bottles/box; 1 bottle/box; 5 bottles/box (Can be customized based on customer's order.) Shelf Life: 24 months Dosage and Administration: It is administrated as a slow intravenous infusion. Before use, add the powder (0.3g) into 50 to 100ml of normal saline or 5% glucose solution for dilution, liquid concentration is less than 6mg/ml, usually, the rate is not exceeded 20mg per minute. 剂型 Dosage Form 生产线(条) Poduction Lines 年产能 Annual Capacity  注射剂 Injection 8 650,000,000 口服固体制剂 Oral Solid 3 700,000,000 原料药和中间体 API & Intermediates 3 8,000 Kg 中药前处理和提取 TCM Extraction 2 5,000,000 Kg  Baiyu provide CDMO service for: FDFs & APIs Primary & secondary packaging Warehousing Commercial scale, pilot scale, laboratory scale You are warmly welcomed to contact us for business cooperation. sales@baiyu.cn www.baiyujituan.com
Azithromycin for Injection
Azithromycin for Injection
Active ingredients: azithromycin. Description: a white crystalline powder. Dosage Form: lyophilized powder for injection. Indications: Azithromycin for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below 1.1 Community-Acquired Pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae in patients who require initial intravenous therapy. 1.2 Pelvic Inflammatory Disease due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis in patients who require initial intravenous therapy. If anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with azithromycin for injection. Strength: 0.25g(250,000IU),0.5g(500,000IU) Storage: Keep airtight in a dry and cool place. Packaging: Tubular vial, 1 vial/box (Can be customized based on customer's order.) Shelf Life:24 months Dosage and Administration: This product is fully dissolved with the appropriate amount of ** for injection, configured to 0.1g / ml and then added to 250ml or 500ml of 0.9% sodium chloride injection or 5% glucose injection.The final azithromycin concentration is 1.0 ~ 2.0mg / ml, Administrated as a intravenous infusion. The infuscated concentration and rate of infusion for azithromycin for injection should be either 1 mg/mL over 3 hr or 2 mg/mL over 1 hr. The infuscated concentration should not be over 2.0mg/ml and the rate of infusion should not less than 60 min. 1. Community-Acquired Pneumonia The recommended dose of azithromycin for injection for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250 mg tablets to complete a 7- to 10-day course of therapy. The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance with clinical response. 2. Pelvic Inflammatory Disease The recommended dose of azithromycin for injection for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy. The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance with clinical response.
Ambroxol hydrochloride Injection
Ambroxol hydrochloride Injection
Active ingredients: ambroxol hydrochloride. Description: Colorless transparent liquid. Dosage Form: liquid injection. Strength: 1ml: 7.5mg; 2ml:15mg; 4ml:30mg Indications: 1. For acute and chronic lung disease with abnormal secretion of sputum and sputum dysfunction. For instance, exacerbation of bronchitis, asthmatic bronchitis and bronchial asthma requiring expectorant treatment; 2. For prevention treatment of respiratory complications after the surgery; 3. For the treatment of IRDS. Storage: Store below 30℃ keeping an airtight place. Packaging: Brown glass ampoule, 5 bottles/box; 10 bottles/box; 20 bottles/box (Can be customized based on customer's order.) Shelf Life: 36 months Dosage and Administration: Adult and children over 12 years old: 15mg two or three times a day, severe cases can be increased to 30mg each time. Children 6-12 years old: 15mg two or three times a day. Children 2-6 years old: 7.5mg three times a day. Children under 2 years old: 7.5mg twice a day. Administrated as a slow intravenous infusion.     Baiyu provide CDMO service for: FDFs & APIs Primary & secondary packaging Warehousing Commercial scale, pilot scale, laboratory scale You are warmly welcomed to contact us for business cooperation. 剂型 Dosage Form 生产线(条) Production Lines 年产能 Annual Capacity  注射剂 Injection 8 650,000,000 口服固体制剂 Oral Solid 3 700,000,000 原料药和中间体 API & Intermediates 3 8,000 Kg 中药前处理和提取 TCM Extraction 2 5,000,000 Kg  我们承接CDMO业务,欢迎同行朋友来电合作,了解详情。
四川宏明博思药业有限公司
注册资本不愿意公开
公司地址
四川省成都市成都高新区合作路343号
联系人
查看联系方式
快速询盘
询盘主题
请输入询盘主题
询盘信息
请输入询盘信息
快速发送询盘
× 大图预览
2006-2026 上海博华国际展览有限公司版权所有(保留一切权利) 沪ICP备05034851号-57